EVA CATALAN: Open Payments
NPI 1174125272 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,600 in 155 payments from 39 companies in 2025. Trend: 2023 $399 · 2024 $4,482 · 2025 $4,600
Food & beverage: $3,423Long term medical supply or device loan: $1,098Education: $79
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 23 | $1,357 |
| AstraZeneca Pharmaceuticals LP | 12 | $297 |
| Janssen Biotech, Inc. | 8 | $250 |
| Tempus AI, Inc | 6 | $193 |
| ABBVIE INC. | 7 | $187 |
| PFIZER INC. | 8 | $165 |
| Daiichi Sankyo Inc. | 6 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $148 |
| Gilead Sciences, Inc. | 7 | $139 |
| Merck Sharp & Dohme LLC | 7 | $136 |
Products named: KISQALI, ENHERTU, XT CDX, Trodelvy, IMFINZI, RYBREVANT, EPKINLY, KEYTRUDA.
Industry payments across TX — which companies pay providers there.
